Skip to main content

Table 5 Characteristics of included studies

From: The value of contrast‐enhanced ultrasound in determining the location of sentinel lymph nodes in breast cancer

Author, year Patients (n) Injection site Injection dose Identification rate Number of SLNs Localization method
Liu,2019 [24] 75 Intradermally inject at 3,6,9,12 o’clock around the arela 0.5ml x 4 94.67 %
(71/75)
116 Skin marked
Li,2019 [23] 453 Intradermally inject at 3,6,9,12 o’clock around the arela 0.6ml x 4 98.2 %
(445/453)
765 Skin marked
Kenzo,2019 [22] 75 Intradermally and subdermally inject at 3,6,9,12 o’clock around the arela 0.25ml x 8 100 %
(100/100)
92 Skin marked
Zhong,2018 [19] 126 Intradermally inject at outer upper quadrant near the areola 2ml 100 %
(126/126)
164 FNA
Xie,2015 [18] 101 Intradermally inject at outer upper quadrant near the areola 1.5ml 97.03 % (98/101) 115 Guidewire
Zhao,2018 [20] 110 Intradermally inject at the periareolar area 0.4ml
(One or two additional injections if failed)
96.4 %
(106/110)
134 Skin marked